Yu FP, Amintas S, Levade T, Medin JA. Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet journal of rare diseases. 2018;13(1):1-19.

Liyanage DS, Pathberiya LS, Gooneratne IK, Vithanage KK, Gamage R. Association of type IV spinal muscular atrophy (SMA) with myoclonic epilepsy within a single family. International Archives of Medicine. 2014;7(1):1-4.

Dyment D, Sell E, Vanstone M, Smith A, Garandeau D, Garcia V, et al. Evidence for clinical, genetic and biochemical variability in spinal muscular atrophy with progressive myoclonic epilepsy. Clinical genetics. 2014;86(6):558-63.

Gebai A, Gorelik A, Li Z, Illes K, Nagar B. Structural basis for the activation of acid ceramidase. Nature communications. 2018;9(1):1621.

Najafi A, Tasharrofi B, Zandsalimi F, Rasulinezhad M, Ghahvechi Akbari M, Zamani G, et al. Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME): three new cases and review of the mutational spectrum. Italian journal of pediatrics. 2023;49(1):64.

Jankovic J, Rivera VM. Hereditary myoclonus and progressive distal muscular atrophy. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society. 1979;6(3):227-31.

Zhou J, Tawk M, Tiziano FD, Veillet J, Bayes M, Nolent F, et al. Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. The American Journal of Human Genetics. 2012;91(1):5-14.

Jankovic J, Rivera V. Hereditary myoclonus and progressive muscular atrophy: a new syndrome. Transactions of the American Neurological Association. 1978;103:116-8.

Karimzadeh P, Najmabadi H, Lochmuller H, Babaee M, Dehdahsi S, Miryounesi M, et al. Five patients with spinal muscular atrophy-progressive myoclonic epilepsy (SMA-PME): a novel pathogenic variant, treatment and review of the literature. 2022.